• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA takes closer look at retinophathy drug

Article

Indianapolis-Eli Lilly & Co.'s ruboxistaurin mesylate (proposed brand name Arxxant), a possible treatment for diabetic retinopathy, has received priority review status by the FDA.

Indianapolis-Eli Lilly & Co.'s ruboxistaurin mesylate (proposed brand name Arxxant), a possible treatment for diabetic retinopathy, has received priority review status by the FDA.

In preclinical trials, data showed that ruboxistaurin inhibits the activity of the protein kinase C beta enzyme. Overactivation of this enzyme has been linked to the underlying process of microvascular damage, caused by diabetes.

In a phase III clinical trial, ruboxistaurin significantly reduced the occurrence of sustained moderate visual loss in patients being treated for moderate-to-very-severe diabetic retinopathy. This 3-year trial involved 685 patients.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.